McKenzie Kathryn B 4
4 · NEOGENOMICS INC · Filed Dec 12, 2019
Insider Transaction Report
Form 4
McKenzie Kathryn B
Principal Accounting Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2019-12-10−8,000→ 40,000 totalExercise: $8.03From: 2019-02-26Exp: 2023-02-26→ Common Stock (8,000 underlying) - Sale
Common Stock
2019-12-10$26.37/sh−8,000$210,960→ 2,273 total - Exercise/Conversion
Common Stock
2019-12-10$8.03/sh+8,000$64,240→ 10,273 total
Holdings
- 25,000
Stock Option (Right to Buy)
Exercise: $9.07From: 2018-10-18Exp: 2022-10-18→ Common Stock (25,000 underlying) - 13,894
Stock Option (Right to Buy)
Exercise: $19.60From: 2020-03-01Exp: 2024-03-01→ Common Stock (13,894 underlying)
Footnotes (3)
- [F1]On February 26, 2018, Ms. McKenzie was granted an option to purchase 48,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date.
- [F2]On October 18, 2017, Ms. McKenzie was granted an option to purchase 25,000 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first three anniversary dates of the grant date.
- [F3]On March 1, 2019, Ms. McKenzie was granted an option to purchase 13,894 shares of NeoGenomics, Inc. common stock. The options vest ratably over the first four anniversary dates of the grant date.